TriGemX Bio

Deals and Financing

TriGemX Raises $94 Million for Phase 3 Migraine Trials

TriGemX Bio, formerly Kallyope, announced a $94 million financing to run Phase 3 studies of elismetrep, an oral TRPM8 blocker for acute migraine. The capital is new and the pivotal program is underway, but…

admin
October 1, 2026

Leadership Tracker

TriGemX Installs New CEO and CFO During Phase 3 Launch

TriGemX Bio appointed Jeff Goater chief executive officer and Aninda Katragadda chief financial officer as the renamed company raised $94 million and launched pivotal elismetrep development. The coordinated financing, rebrand and leadership change are…

admin
October 1, 2026

TriGemX Raises $94 Million for Phase 3 Migraine Trials

TriGemX Installs New CEO and CFO During Phase 3 Launch

Saturday Rounds